{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:34:13Z","timestamp":1789842853204,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"DOI":"10.7759\/cureus.79630","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T16:20:43Z","timestamp":1740500443000},"source":"Crossref","is-referenced-by-count":3,"title":["Drug-Induced Immune Hemolytic Anemia Following Dapagliflozin Administration: A Case Report"],"prefix":"10.7759","author":[{"given":"Bergen","family":"Lemack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Kupovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2010.06.004","article-title":"Immune hemolytic anemia associated with drug therapy","volume":"24","author":"Garratty G","year":"2010","unstructured":"Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010, 24:143-50. 10.1016\/j.blre.2010.06.004","journal-title":"Blood Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.73","article-title":"Drug-induced immune hemolytic anemia","author":"Garratty G","year":"2009","unstructured":"Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009, 73-9. 10.1182\/asheducation-2009.1.73","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0257-7","article-title":"Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature","volume":"19","author":"Leicht HB","year":"2018","unstructured":"Leicht HB, Weinig E, Mayer B, Viebahn J, Geier A, Rau M. Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature. BMC Pharmacol Toxicol. 2018, 19:67. 10.1186\/s40360-018-0257-7","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14299","article-title":"Furosemide-induced haemolytic anaemia in an extreme elderly patient","volume":"10","author":"Ho IW","year":"2023","unstructured":"Ho IW, Huang CC. Furosemide-induced haemolytic anaemia in an extreme elderly patient. ESC Heart Fail. 2023, 10:1449-53. 10.1002\/ehf2.14299","journal-title":"ESC Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S50963","article-title":"Dapagliflozin for the treatment of type 2 diabetes: a review of the literature","volume":"8","author":"Saeed MA","year":"2014","unstructured":"Saeed MA, Narendran P. Dapagliflozin for the treatment of type 2 diabetes: a review of the literature. Drug Des Devel Ther. 2014, 8:2493-505. 10.2147\/DDDT.S50963","journal-title":"Drug Des Devel Ther"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.21307\/immunohematology-2019-098","article-title":"Drug-induced immune hemolytic anemia: the last 30 years of changes","volume":"30","author":"Arndt PA","year":"2014","unstructured":"Arndt PA. Drug-induced immune hemolytic anemia: the last 30 years of changes. Immunohematology. 2014, 30:44-54.","journal-title":"Immunohematology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPBVLJZH6W6RQM","article-title":"Pathology consultation on drug-induced hemolytic anemia","volume":"136","author":"Pierce A","year":"2011","unstructured":"Pierce A, Nester T. Pathology consultation on drug-induced hemolytic anemia. Am J Clin Pathol. 2011, 136:7-12. 10.1309\/AJCPBVLJZH6W6RQM","journal-title":"Am J Clin Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1517\/14740330802577351","article-title":"Drug-induced immune hemolytic anemia","volume":"8","author":"Salama A","year":"2009","unstructured":"Salama A. Drug-induced immune hemolytic anemia. Expert Opin Drug Saf. 2009, 8:73-9. 10.1517\/14740330802577351","journal-title":"Expert Opin Drug Saf"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinpr.2024.100341","article-title":"A case of ceftriaxone-induced immune haemolytic anaemia in an ambulatory care setting","volume":"21","author":"Mistry R","year":"2024","unstructured":"Mistry R, Moore LSP, Mughal N, Godfrey A, Hughes S. A case of ceftriaxone-induced immune haemolytic anaemia in an ambulatory care setting. Clin Infect Pract. 2024, 21:100341. 10.1016\/j.clinpr.2024.100341","journal-title":"Clin Infect Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9841097","article-title":"Co-amoxiclav induced immune haemolytic anaemia: a case report","volume":"2020","author":"Karunathilaka HG","year":"2020","unstructured":"Karunathilaka HG, Chandrasiri DP, Ranasinghe P, Ratnamalala V, Fernando AH. Co-amoxiclav induced immune haemolytic anaemia: a case report. Case Rep Hematol. 2020, 2020:9841097. 10.1155\/2020\/9841097","journal-title":"Case Rep Hematol"},{"key":"ref11","article-title":"Laboratory evaluation of immune hemolytic anemias","author":"Tripathi AK","year":"2024","unstructured":"Tripathi AK, Chuda R. Laboratory evaluation of immune hemolytic anemias. StatPearls [Internet]. StatPearls Publishing, Treasure Island, Florida; 2024."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01173.x","article-title":"One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm","volume":"47","author":"Johnson ST","year":"2007","unstructured":"Johnson ST, Fueger JT, Gottschall JL. One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm. Transfusion. 2007, 47:697-702. 10.1111\/j.1537-2995.2007.01173.x","journal-title":"Transfusion"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.02.011","article-title":"Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia","volume":"30","author":"Nishida H","year":"2006","unstructured":"Nishida H, Murase T, Ueno H, Park JW, Yano T, Ikeda Y. Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia. Leuk Res. 2006, 30:1589-90. 10.1016\/j.leukres.2006.02.011","journal-title":"Leuk Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08784.x","article-title":"Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study","volume":"154","author":"Garbe E","year":"2011","unstructured":"Garbe E, Andersohn F, Bronder E, et al.. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol. 2011, 154:644-53. 10.1111\/j.1365-2141.2011.08784.x","journal-title":"Br J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8666","article-title":"Drug-induced immune hemolytic anemia due to amoxicillin-clavulanate: a case report and review","volume":"12","author":"Chan Gomez J","year":"2020","unstructured":"Chan Gomez J, Saleem T, Snyder S, Joseph M, Kanderi T. Drug-induced immune hemolytic anemia due to amoxicillin-clavulanate: a case report and review. Cureus. 2020, 12:e8666. 10.7759\/cureus.8666","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2450\/2014.0237-13","article-title":"Severe drug-induced immune haemolytic anaemia due to ceftazidime","volume":"12","author":"Chen F","year":"2014","unstructured":"Chen F, Zhan Z. Severe drug-induced immune haemolytic anaemia due to ceftazidime. Blood Transfus. 2014, 12:435-7. 10.2450\/2014.0237-13","journal-title":"Blood Transfus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000440673","article-title":"Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre","volume":"42","author":"Mayer B","year":"2015","unstructured":"Mayer B, Bartolm\u00e4s T, Y\u00fcrek S, Salama A. Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre. Transfus Med Hemother. 2015, 42:333-9. 10.1159\/000440673","journal-title":"Transfus Med Hemother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/635670","article-title":"Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia","volume":"2015","author":"Barcellini W","year":"2015","unstructured":"Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers. 2015, 2015:635670. 10.1155\/2015\/635670","journal-title":"Dis Markers"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2019-725","article-title":"Direct coombs test-negative autoimmune hemolytic anemia and low-affinity IgG class antibodies","volume":"13","author":"Sokol RJ","year":"1997","unstructured":"Sokol RJ, Booker DJ, Stamps R, Jalihal S, Paul B. Direct coombs test-negative autoimmune hemolytic anemia and low-affinity IgG class antibodies. Immunohematology. 1997, 13:115-8. 10.21307\/immunohematology-2019-725","journal-title":"Immunohematology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula S","year":"2014","unstructured":"Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014, 53:17-27. 10.1007\/s40262-013-0104-3","journal-title":"Clin Pharmacokinet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/315975-drug-induced-immune-hemolytic-anemia-following-dapagliflozin-administration-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T16:20:47Z","timestamp":1740500447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/315975-drug-induced-immune-hemolytic-anemia-following-dapagliflozin-administration-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.79630","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}